---
id: "action-strategic-vc-partnerships"
type: "action-item"
source_timestamps: ["§ 4. Extend AMC research investments beyond early-stage science."]
tags: ["finance", "venture-capital"]
related: ["concept-amc-strategic-financing", "entity-cleveland-clinic", "entity-khosla-ventures"]
action: "Partner with venture capital funds to finance late-stage clinical development of internal innovations."
outcome: "Prevention of viable early-stage innovations stalling due to lack of traditional grant funding."
speakers: ["Anaeze C. Offodile II", "Kushal T. Kadakia", "Yashodhara Dash", "Whitney Snider", "Joseph C. Wu", "Selwyn M. Vickers"]
sources: ["tail2"]
sourceVaultSlug: "hbr-seg-tail2"
originDay: 2
articleStem: "hbr-tail-131-medical-drug-discovery"
sourceUrl: "https://hbr.org/2026/04/u-s-medical-centers-need-a-new-model-for-drug-discovery-and-development"
sourceTitle: "U.S. Medical Centers Need a New Model for Drug Discovery and Development"
---
# Form Strategic VC Partnerships

**Action:** Bridge the funding gap for late-stage clinical development by **co-investing with or forming deep partnerships with traditional venture-capital funds**, offering the AMC's clinical environment as an incubation **"sandbox"** — the mechanism of [[concept-amc-strategic-financing]].

**Mechanism / example:** [[entity-cleveland-clinic-d2]] + [[entity-khosla-ventures]] (Pillar 4 of [[framework-amc-innovation-acceleration]]), addressing [[claim-traditional-funding-insufficient]].

**Outcome:** prevention of viable early-stage innovations stalling for lack of traditional grant funding. **Caution:** VC involvement can bias portfolios toward commercially attractive indications and create mission tension — see [[question-mission-fidelity]].